Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: HPBCD

December 7, 2022 Drug delivery / Pharma applications

An Updated Overview of Cyclodextrin-Based Drug Delivery Systems for Cancer Therapy

Cyclodextrins (CDs) attracted increasing interest over the past few years, leading to the emergence of promising anti-tumor nanomedicines. Tackling their

Continue reading

November 18, 2022 CD as API / CD derivatives

Nature.com: HPBCD treatment improves learning and executive function in Alzheimer model mice

Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of

Continue reading

November 18, 2022 Analysis / Non-pharma applications

HPBCD-enabled metal nanoclusters for selective labeling of lysosomes

The controllable self-assembly of metal nanoclusters (NCs) has attracted great interest because of the morphological versatility and accompanying luminescence properties,

Continue reading

November 16, 2022 CD derivatives / Drug delivery / Pharma applications

First Patient Enrolled in Phase 1 Study of Midatech’s Panobinostat / HPBCD (MTX-110) for Recurrent Glioblastoma

Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announced on 14 November

Continue reading

November 15, 2022 Drug delivery / Pharma applications

Oral Xe-Cyclodextrin for cardiovascular protection

Cardiac hypertrophy often causes impairment of cardiac function. Xenon (Xe), a naturally occurring noble gas, is known to provide neurological

Continue reading

October 25, 2022 CD as API / Pharma applications

Australian company pioneering Cavadextrin for regression of atherosclerosis

Newsmaker, the Australian Press Release Distribution Service has published the news on “An Australian pioneering a medical breakthrough treatment that

Continue reading

October 11, 2022 CD as API / Pharma applications

Inclusion Solves Insolubility ―Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C

Cyclodextrins (CDs) are used not only as pharmaceutical excipients but also as active pharmaceutical ingredients. CDs can act as artificial

Continue reading

October 5, 2022 CD as API / CD derivatives

Monosubstituted Maltosyl Cyclodextrins for the Potential Treatment of NPC

Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it

Continue reading

September 29, 2022 CD as API / Life sciences / Uncategorized

MIT scientists filed patent for HPBCD treatment in Alzheimer’s disease

Li-Huei Tsai, director of Picower Institute for Learning and Memory (Massachusetts Institute of Technology) and her coworkers recently filed a patent

Continue reading

September 22, 2022 Drug delivery / Events / Pharma applications

Inaugural Lecture of Prof. Szente at the Hungarian Academy of Sciences

Lajos Szente, Ph.D., D.Sc., one of the founders and former CEO (now Scientific Advisor) of CycloLab at the company and

Continue reading

Posts navigation

1 2 3 … 15 Next Posts»

Recent Posts

  • Bacteroides uniformis and its preferred substrate, α-cyclodextrin, enhance endurance exercise performance in mice and human males
  • Waterproof and durable luminescent textiles with HPBCD for marine rescue
  • Small anticancer drug release by light
  • Patent application on reduction of envelope viral particle number in a composition containing cyclodextrin
  • γ-Cyclodextrin/Epigallocatechin-3-gallate Inclusion Complexes as Efficient Antioxidants for Preservation of Shrimp Surimi Products

Tags

alpha-CD antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (35)
  • CD as API (199)
  • CD derivatives (251)
  • Cosmetics and toilettry (21)
  • Drug delivery (416)
  • E-ducation (54)
  • Environmental (76)
  • Events (157)
  • Food (120)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (13)
  • Non-pharma applications (209)
  • Other industrial use (58)
  • Pharma applications (677)
  • Supramolecular systems (25)
  • Uncategorized (41)

Top Posts

  • Lanosterol eye drops for cataract treatment
  • Waterproof and durable luminescent textiles with HPBCD for marine rescue
  • γ-Cyclodextrin/Epigallocatechin-3-gallate Inclusion Complexes as Efficient Antioxidants for Preservation of Shrimp Surimi Products
  • Small anticancer drug release by light
  • New book: Cyclodextrins - new Perspectives
  • Cyclodextrin Metal-Organic Framework as a Broad-Spectrum Potential Delivery Vehicle for the Gasotransmitters
  • MIT scientists filed patent for HPBCD treatment in Alzheimer's disease
  • Pilocarpine eye drops (Vuity)
  • Current Overview of Cyclodextrin-Based Nanocarriers for Enhanced Antifungal Delivery
  • Improved fittness of mice treated with gamma-cyclodextrin

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 521 other subscribers
 

Loading Comments...